3 0 0 0 OA ダイオウ,およびダイオウとセンナ配合 OTC 医薬品中のセンノシド A,B 量
- 著者
- 椎 崇 井口 巴樹 黒田 明平 鈴木 真理香 島﨑 珠美 三巻 祥浩
- 出版者
- 一般社団法人 日本医薬品情報学会
- 雑誌
- 医薬品情報学 (ISSN:13451464)
- 巻号頁・発行日
- vol.25, no.1, pp.24-30, 2023-05-30 (Released:2023-05-31)
- 参考文献数
- 10
Objective: Sennosides A and B, which are dianthrone glycosides contained in Rhubarb and Senna Leaf, exhibit laxative effect. Although a number of over-the-counter (OTC) drugs used as laxatives contain Rhubarb or Rhubarb and Senna Leaf, the total amounts of sennosides A and B are not mentioned in the package insert. To determine the total amounts of sennosides A and B in OTC drugs containing Rhubarb or Rhubarb and Senna Leaf, quantitative analyses of sennosides A and B were performed for 24 OTC drugs.Methods: Sennosides A and B were extracted from 24 OTC drugs and quantitatively analyzed by high-performance liquid chromatography. Statistical analyses were carried out by a one-way analysis of variance followed by Dunnett's test or Tukey's test.Results: The OTC drugs contained sennosides A and B in the range of 1.5-10 mg in the minimum daily dosage and in the range of 2.7-17 mg in the maximum daily dosage. In 11 of the OTC drugs (Products Nos. 1-5, 11, 12, and 15-18), the maximum daily dosage contained almost equal or higher amounts of sennosides A and B compared to that in a tablet of the prescription medicine Pursennid® 12 mg. Furthermore, the amounts of sennosides A and B in the maximum daily dosage were significantly higher in products Nos. 1 and 11 and lower in products Nos. 8-10, 14, and 20-24 compared to those of a tablet of Pursennid® 12 mg.Conclusion: Although some OTC drugs have the same Rhubarb content, the total amounts of sennosides A and B can vary. Thus,there is no correlation between the Rhubarb content and total amounts of sennosides A and B. This is because of the inconsistent quality of Rhubarb and/or the differences in the manufacturing methods of the OTC drugs containing Rhubarb. Because the total amounts of sennosides A and B cannot be estimated based on the Rhubarb content, a constipated patient should start taking an OTC drug containing Rhubarb at the minimum daily dosage. It is also recommended that the total amounts of sennosides A and B are mentioned in the package insert of OTC drugs containing Rhubarb or Rhubarb and Senna Leaf.
- 著者
- 椎 崇 黒田 明平 社本 典子 三巻 祥浩
- 出版者
- 一般社団法人 日本老年医学会
- 雑誌
- 日本老年医学会雑誌 (ISSN:03009173)
- 巻号頁・発行日
- vol.57, no.1, pp.72-80, 2020-01-25 (Released:2020-02-18)
- 参考文献数
- 22
- 被引用文献数
- 5 7
目的:生薬・オウゴンを構成生薬とする漢方薬の重大な副作用として,間質性肺炎や肝機能障害が挙げられる.バイカリン(BL)はオウゴンの主要成分であり,これら副作用への関与が強く示唆されている.本研究では,漢方薬を安全に使用するための基礎資料を得ることを目的に,オウゴンが配合される漢方薬中のBL量を定量した.方法:オウゴンが1日量として1.5~4 g配合される漢方薬28処方の煎液と医療用エキス製剤のBL量を定量した.結果:同一の漢方処方では,煎液とエキス製剤間でBL量に1.7倍から4倍の差が認められ,いずれも煎液中のBL量が多かった.さらに,小柴胡湯,乙字湯,大柴胡湯,柴朴湯,黄連解毒湯,柴苓湯の各エキス製剤における製造会社間のBL量を比較した.その結果,小柴胡湯,乙字湯,大柴胡湯,柴朴湯エキス製剤において,それぞれ最大2.6倍,1.6倍,1.5倍,1.3倍の有意な差が認められた.一方,黄連解毒湯と柴苓湯のエキス製剤においては,製造会社間で有意な差は認められなかった.考察:医療現場においては,漢方薬の煎液にはエキス剤と比較して1.7~4倍のBLが含まれることを認識し,煎じ薬はより効果が期待できる反面,副作用の発症頻度も増える可能性があることを考慮して使用するべきと考える.また,漢方薬の調製に使用したオウゴンの量のほか,製剤中に含まれるBL量とそのアグリコン(非糖部)であるバイカレイン(BA)量に関する情報も示すことを提案する.
2 0 0 0 OA 漢方薬の煎液およびエキス製剤の成分分析 -カンゾウ配合漢方薬中のグリチルリチン酸量-
- 著者
- 黒田 明平 木下 歩美 椎 崇 社本 典子 三巻 祥浩
- 出版者
- 一般社団法人日本医療薬学会
- 雑誌
- 医療薬学 (ISSN:1346342X)
- 巻号頁・発行日
- vol.43, no.11, pp.619-629, 2017-11-10 (Released:2018-11-10)
- 参考文献数
- 17
- 被引用文献数
- 3 3
Pseudohyperaldosteronism and associated hypokalemia are serious adverse effects caused by glycyrrhizinic acid (GA) present in Kampo medicines containing Glycyrrhizae Radix (GR); GA is the major component of GR. To obtain knowledge about the effective and safe use of Kampo medicines, we analyzed the quantities of GA in Kampo medicines by HPLC. The quantities of GA in 13 Kampo decoctions containing GR (2-6 g/day) were found to be almost 2-3.5 fold higher than those of the corresponding Kampo extract products. Among the Kampo extract products containing GR (3 g/day), the GA quantity in Shoseiryuto was significantly lower compared with that in the others, and Pinelliae Tuber as well as Schisandrae Fructus were found to contribute to the decrease in GA quantity. The GA quantity in the Yokukansakachinpihange decoction was found to be lower than that in the Yokukansan decoction; this was caused by the presence of Pinelliae Tuber and Citri Unshiu Pericarpium. Analysis of inter-product variations in GA quantities among the Kampo extract products revealed a maximum 2.6-fold difference in the quantities in the Shoseiryuto extract products from different companies. Our analyses show that GA quantities in Kampo medicines are influenced by the presence of concomitant crude drug constituents. This results in differences in GA quantities between decoctions and extract products having the same Kampo formula, and also among the Kampo extract products from different companies. It is recommended that GA quantities in Kampo extract products should be presented to prevent the adverse effects caused by GA.